Trichostatin A

 48,83

Trichostatin A (TSA) is a commonly used inhibitor of HDAC (histone deacetylase). Trichostatin A is cell permeable and selectively inhibits HDACs, but not the NAD-dependent SIRT family of deacetylases. The inhibition of HDACs leads to increased levels of histone acetylation and increased transcriptional levels of some genes, as well as increased acetylation levels of some other proteins to alter their activity or stability. Trichostatin A can inhibit cell cycle and is currently considered as a potential anti-cancer drug. Package: 2mg/ml×50ul

Description

Trichostatin A (TSA) is a commonly used inhibitor of HDAC (histone deacetylase). Trichostatin A is cell permeable and selectively inhibits HDACs, but not the NAD-dependent SIRT family of deacetylases. The inhibition of HDACs leads to increased levels of histone acetylation and increased transcriptional levels of some genes, as well as increased acetylation levels of some other proteins to alter their activity or stability. Trichostatin A can inhibit cell cycle and is currently considered as a potential anti-cancer drug.

This product has a molecular weight of 302.37, a molecular formula of C17H22N2O3, a CAS Number of 58880-19-6, and a purity >98%.

This product is supplied as a stock solution of 2mg/ml in DMSO.

Packing List:

Item Component Quantity
S1893-100µg Trichostatin A (HDAC Inhibitor) 2mg/ml×50ul
Manual 1 copy

Storage Conditions:

Store at -20℃ in the dark for up to 1 year.

Precautions:

This product is harmful to the human body. Please avoid direct contact or inhalation.

This product reconstituted in DMSO will solidify and stick to the tube at low temperatures such as 4℃. The solidified product should be reliquified by warming to room temperature before use.

This product is for R&D only. Not for drug, household, or other uses.

For your safety and health, please wear a lab coat and disposable gloves during the operation.

Instruction

Instructions for Use:
1.This product is typically used at 10nM-1µM. The optimal working concentration should be determined for different cells, tissues, and experimental purpose by referring to relevant literature or by exploring through experiments.

Product files

MSDS

https://scandicbiotech.com/wp-content/uploads/2026/04/S1893.pdf

References

Related papers:

1. Liang Q, Ding J, Xu R, Xu Z, Zheng S.
.
Int J Cancer. 2010 Oct 15;127(8):1833-43. (IF 5.145)
3. Liang Q, Xu Z, Xu R, Wu L, Zheng S.
.
PLoS One. 2012;7(1):e29950. (IF 2.74)
4. Li L, Bao H, Wu J, Duan X, Liu B, Sun J, Gong W, Lv Y, Zhang H, Luo Q, Wu X, Dong J.
.
Int Immunopharmacol. 2012 May;13(1):15-22. (IF 3.943)
5. Wang H, Cheng H, Wang K, Wen T.
.
J Neural Transm. 2012 Nov;119(11):1307-15. (IF 3.505)
6. Chang X, Zhang S, Ma J, Li Z, Zhi Y, Chen J, Lu Y, Dai D.
.
Cell Biochem Biophys. 2013 May;66(1):93-101. (IF 2.073)
7. Huang D, Li ZH, You D, Zhou Y, Ye BC.
.
APPL MICROBIOL BIOT. 2015 Feb;99(3):1399-413. (IF 3.53)
8. Zhang B, Luo Q, Chen Z, Shi Y, Ju Y, Yang L, Song G.
.
SCI REP-UK. 2016 Jan 8;6:18809. (IF 3.998)
10. Zhou B, Li H, Xing C, Ye H, Feng J, Wu J, Lu Z, Fang J, Gao S5.
.
Biochem Pharmacol. 2016 Dec 30. pii: S0006-2952(16)30502-0. (IF 4.96)
11. Zhou B, Li H, Xing C, Ye H, Feng J, Wu J, Lu Z, Fang J, Gao S.
.
Biochem Pharmacol. 2017 Mar 15;128:12-25. (IF 4.96)
12. Wang L, Tan RZ, Zhang ZX, Yin R, Zhang YL, Cui WJ, He T.
.
Oncol Lett. 2018 Jan;15(1):1058-1066. (IF 2.311)
13. Wang T, Cheng J, Wang S, Wang X, Jiang H, Yang Y, Wang Y, Zhang C, Liang W, Feng H
.
Brain Res Bull. 2018 Jun;140:299-310. (IF 3.37)
14. Jiang D, Li M, Yu Y, Shi H, Chen R
.
J Med Virol. 2019 Sep 91(9):1643-1651. (IF 2.021)